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Abstract: Material choice is a fundamental consideration when it comes to designing a solid dosage
form. The matrix material will ultimately determine the rate of drug release since the physical
properties (solubility, viscosity, and more) of the material control both fluid ingress and disintegration
of the dosage form. The bulk properties (powder flow, concentration, and more) of the material
should also be considered since these properties will influence the ability of the material to be
successfully manufactured. Furthermore, there is a limited number of approved materials for the
production of solid dosage forms. The present study details the complications that can arise when
adopting pharmaceutical grade polymers for fused-filament fabrication in the production of oral
tablets. The paper also presents ways to overcome each issue. Fused-filament fabrication is a
hot-melt extrusion-based 3D printing process. The paper describes the problems encountered in
fused-filament fabrication with Kollidon® VA64, which is a material that has previously been utilized
in direct compression and hot-melt extrusion processes. Formulation and melt-blending strategies
were employed to increase the printability of the material. The paper defines for the first time the
essential parameter profile required for successful 3D printing and lists several pre-screening tools
that should be employed to guide future material formulation for the fused-filament fabrication of
solid dosage forms.
Keywords: 3D printing; fused-filament fabrication; additive manufacturing; hot-melt extrusion;
formulation; melt-blending; solid dosage forms; tablets
1. Introduction
Three-dimensional printing (3DP) is finding increasing utility in the manufacture of
pharmaceutical dosage forms [1]. The production process is available in some different formats [2],
but it can be best defined as a process that creates a physical object from a digital model through
the layer-by-layer deposition of material. Potential pharmaceutical applications for 3DP are diverse
and span conventional dosage forms such as tablets and implants as well as less typical pulsatory
devices [3]. Spritam® is the first FDA approved 3D printed dosage form and is an orodispersible
tablet containing different doses of the anti-seizure drug levetiracetam [4]. The manufacturers harness
3DP to enable high dosing (1000 mg) while maintaining a highly porous structure that aids rapid
disintegration necessary for orodispersibles. Innovation lies at the heart of the drive towards 3D printed
dosage forms meant for both the creation of more complex devices and to meet the requirements of
on-demand manufacturing and precision medicine [1].
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Fused-filament fabrication (FFF) is a method of 3D printing that incorporates the hot-melt
extrusion (HME) process for manufacturing a thermoplastic filament that can be fed directly to
an extrusion head for melt-deposition in a pre-programmed x-y-z axis. The process is also commonly
known by the trademarked name Fused Deposition Modelling™. HME is a well-established process
for the production of pharmaceutical dosage forms, which ensures solvent-free production, low-cost
scale-up, and enhanced solubility for poorly water-soluble drugs [5]. FFF is a mainstay among
3DP amateur enthusiasts since the printers are relatively inexpensive and the filaments come in an
abundance of colors. The technology is gaining interest in pharmaceutical research groups worldwide
that were previously described in the production of a variety of different experimental dosage forms [6].
Producing drug-loaded filaments to strict tolerance of diameter and shape can be slow and cumbersome
without the prerequisite HME processing equipment. For this reason, some groups opt to impregnate
the commercial filament with the drug [7–9] while others can produce drug-loaded filaments for
FFF via the HME process to print experimental tablets [7,10–19], caplets [20,21], implants [22–24],
discs [25–27], and topical devices [28].
Material choice is a fundamental consideration when designing a pharmaceutical dosage form.
Physical properties of the material will influence the rate of release and the type of release with
the matrix polymers ranging from fully biodegradable [29] to non-degradable [30]. Material bulk
properties will also deter the route of manufacturing since certain properties can exclude particular
processes. A further restriction is a limited range of polymer materials with regulatory approval as
excipients for the production of solid dosage forms [31]. For FFF in general, the range of materials
available is very narrow compared with other conventional HME based processes. Thirty materials
available commercially were compared to over three thousand for the other HME-based processes [32].
There is currently no formalized method for pre-screening materials for the FFF process [33] and
there is no definitive property profile of FFF feedstock in the literature for benchmarking materials for
printability. A number of pharmaceutical materials have been investigated for FFF including polyvinyl
alcohol [7–9,11,12,17,20,21,27], cellulose-based polymers [13,19,24,27], polylactic acid [24,25,27,28],
polycaprolactone [22,24,28], ethylene vinyl acetate [23], polyvinylpyrrolidone [15,16], Soluplus® [26,27],
Kollicoat® IR [27], and Eudragit® grades [14,18,24,26,27].
The initial concept of this work was to manufacture oral tablets by direct compression, injection
molding, and FFF for comparison. Kollidon® VA64 (PVP-VA) was chosen as the polymer matrix
material since it is recommended for both direct compaction and HME by the manufacturers BASF [34].
We have previously reported on the use of PVP-VA in the production of both direct-compaction [35]
and injection molded [36] multi-layered vaginal tablets in which the polymer constituted the immediate
release layers. However, our initial trials highlighted some issues including filament brittleness and
stiffness, which prevented the simple adoption of this polymer for the FFF manufacture of similar
tablets. Similar to other pharmaceutical grade polymers [26], PVP-VA has inherent limitations that
prevent FFF based 3DP. These will be discussed in detail. In a wider context, the same issues will be
relevant for similar pharmaceutical grade polymers without the necessary set of physical properties
required for successful FFF-based 3DP. This present work aims for the first time to detail the necessary
material property profile for a pharmaceutical grade polymer to successfully undergo the FFF process
for complete-batch runs, which is defined as a batch that utilizes the full working surface of the
print-bed without operator interference. There is a focus on the inherent compromises that must be
made between printability and final dosage form properties. We outline potential difficulties faced
at every stage of the FFF process and list suitable strategies to deal with each issue. We describe a
melt-blending approach that can be adapted by other researchers to accommodate their specific needs
from a matrix material and simultaneously overcome material shortcomings that prevent FFF 3DP.
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2. Materials and Methods
2.1. Materials
Kollidon® VA64 and Kolliphor® P188 were purchased from BASF Ireland (Cork, Ireland).
Poly (ethylene oxide) (PEO) (average MWT = 300,000) in a white powder form was obtained from
Sigma-Aldrich (Arklow, Ireland). Polycaprolactone (PCL) in powder form (CAPA 6506, average MWT
= 50,000) was obtained from Perstorp (Cheshire, UK). USP grade caffeine was purchased from VWR
International (Dublin, Ireland). Caffeine was chosen as a Biopharmaceutical Classification System
(BCS) Class I model drug since it was available in sufficient quantities to complete the overall study
(of greater scope than this paper), has a melting temperature greater than the processing temperatures,
and was safe for use in the environments the production equipment were located. Table 1 displays all
placebo formulations manufactured in this body of work for their mechanical characterization and for
pre-screening trials.
Table 1. Material formulations of melt-blends used in pre-screening.
Name Composition by Weight (%)
PVP-VA P188 PCL PEO
PVP-VA 100 - - -
PCL - - 100 -
F1 90 10 - -
F2 90 - 10 -
F3 90 - - 10
F4 80 - 20 -
F5 80 - - 20
F6 70 - 30 -
F7 60 - 40 -
F8 50 - 50 -
F9 60 - 30 10
F10 60 10 30 -
F11 30 - 60 10
Five formulations were produced with the model drug caffeine and can be found in Table 2.
These mixtures were produced to perform drug dissolution studies to evaluate the effects of the
formulations and PVP-VA loading on drug release kinetics as well as to compare tablets that were
manufactured via direct compression and 3DP.
Table 2. Material formulations for drug dissolution studies.
Name Composition by Weight (%)
PVP-VA PCL PEO Caffeine
DC 30% PVP-VA 30 55 10 5
DC 60% PVP-VA 60 25 10 5
3DP 30% PVP-VA 30 55 10 5
3DP 40% PVP-VA 40 −45 10 5
3DP 60% PVP-VA 60 25 10 5
2.2. Preparation of Filaments by HME
Thirteen material formulations are outlined in Table 1. Before HME processing, all excipients were
passed through a 450 µm sieve to obtain equivalent particle sizes. Each batch was mixed in a Universal
Motor Drive 400 (Pharmag GmbH, Hamburg, Germany) attached to a cube mixer. The conditions
for mixing all batches were kept the same at 50 RPM for 15 min. Premixed batches were fed to an
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MP19TC25 APV Baker 16 mm co-rotating twin screw extruder (APV Baker, Newcastle-under-Lyme,
UK) equipped with a purpose-built filament for Ming dye. The filament dye has a conical shaped
cavity that narrows it away from the extruder, which finishes in a circular orifice (diameter 2.30 mm).
The gradient temperature profile of the HME process is detailed in Table 3. The screw speed was
set at 80 RPM and the feeding rate was 0.4 kg/h. The extruded batches were hauled off by using a
conveyor belt system consisting of a Teflon belt that was tilted at a 45◦ downward angle from the
extruder die. A second conveyor twin-belt system was set at a sufficient haul-off speed to maintain a
filament diameter of 1.75 ± 0.10 mm necessary for the FFF 3D printing process.
Table 3. Temperature profile for twin-screw compounding HME (hot-melt extrusion) process to
produce filament.
Temperature (◦C)
Zone 1 Zone 2 Zone 3 Zone 4 Zone 5 Zone 6 Flange Die
80 90 100 110 120 130 140 140
2.3. Production Tablets by FFF
FFF using F11 and formulations labelled “3DP” from Table 2 as feedstock material was carried out
using a commercial desktop 3D printer, MakerBot Replicator 2× (Makerbot® Industries, New York, NY,
USA). The printing conditions for the most aesthetic and robust tablets were kept constant by using
the following parameters: extrusion speed (10 mm/s), extruder temperature (150 ◦C), printing bed
temperature (50 ◦C), extruder travel speed (50 mm/s), number of shells (1), roof and floor thickness
(0.5 mm), layer height (0.2 mm), and infill 25% in which the linear infill pattern and the raft and
support options were turned off. A total of 40 tablets were printed using these settings without any
operator intervention after setup. The process was completed in 44 min. The three-dimensional design
for a flat-face plain tablet was created using SolidWorks 2014 (Dassault Systèmes, Waltham, MA, USA)
and saved as an STL extension format (see Figure 1). The STL file was opened using the monitor and
remote control software suite MakerBot Desktop (Makerbot® Industries, New York, NY, USA).
Figure 1. Three-dimensional design of a flat-face plain tablet.
2.4. Mechanical Testing
2.4.1. Dynamic Mechanical Analysis
Dynamic mechanical analysis (DMA) was performed on filaments of all formulations using TA
Instruments DMA Q800 (Dublin, Ireland). The test was performed in single cantilever mode using a
frequency of 1 Hz and an amplitude of 15 µm. The temperature range between −80 ◦C to 150 ◦C with
3 ◦C/min rate was used to determine the storage modulus, the loss modulus, and the glass transition
temperature (tan δ) for all twelve formulations.
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2.4.2. Filament Stiffness
The temperature range −80 ◦C to 150 ◦C with 3 ◦C/min rate was used to determine the stiffness
and glass transition temperature (tan δ) for PVP-VA, PCL, and the eleven formulations. The test was
carried with a constant frequency of 1 Hz and an amplitude of 15 µm using the single cantilever mode.
Equation (1) is the general equation of stiffness.
Sti f f ness =
Load
De f ormation
(1)
Load is defined as the force applied to the material in any given moment to obtain the desired
amplitude expressed in newtons (N). Deformation is the distance the sample has moved from its
original position at the beginning of the test and it is expressed in meters (m).
2.4.3. Filament Brittleness
The calculation of filament brittleness involved two separate tests, which were performed on
25 mm filament lengths of all formulations using a TA Instruments DMA Q800 (Dublin, Ireland).
Storage modulus (E′) values were taken in single cantilever mode at room temperature with a frequency
of 1 Hz. Cylindrical samples had a length of 17.5 mm and varying diameters. The test was performed
in triplicate. Quasi-static 3-point bending of 25 mm filament lengths was performed separately on
the Q800. The force applied to the samples was ramped up at 3 N/minute and the test was stopped
when samples broke or a maximum displacement was achieved. The Brostow-Hagg Lobland-Narkis
Equation (Equation (2)) for brittleness was used to obtain brittleness (B) values [37]. In the equation, E′
is the DMA storage modulus at 1.0 Hz at room temperature and strain-at-break (%), εb is calculated
from room temperature 3-point bending.
B =
1
εb·E′
(2)
2.5. Melt Flow Indexing
Melt flow indexing (MFI) was performed for all formulations in a range of temperatures. The melt
flow rates (MFR) were measured using a Zwick Roell Cflow extrusion plastometer, which was equipped
with a 2 mm orifice die. All testing was performed following the guidelines of the ASTM standard
D1238-13 with a fixed weight of 2.16 kg. Test temperatures were 140 ◦C and 150 ◦C based on the HME
die temperature and FFF printing temperature, respectively.
2.6. Differential Scanning Calorimetry
Differential scanning calorimetry (DSC) was employed for thermal characterization of the virgin
polymers and eleven formulations using a TA Instruments DSC 2920 Differential Scanning Calorimeter
(Dublin, Ireland). Samples weighed between 8–12 mg and were placed in non-hermetical aluminum
pans, which were crimped prior to testing with an empty crimped aluminum pan for reference.
Each sample was summited to a heating cycle to remove thermal history consisting of a ramp from
room temperature to 200 ◦C at a rate of 10 ◦C/min. A cooling cycle to 0 ◦C was set at a rate of 5 ◦C/min.
Data recording was activated and the temperature was ramped up at a rate of 10 ◦C/min until it
reached 200 ◦C.
2.7. Mass Loss Studies
Polymer filaments with a length of 20 mm were tested in duplicates in dissolution media of 0.2 M
hydrochloric (HCl) acid, pH 1.2, and the temperature maintained at 37 ± 0.5 ◦C to mimic the stomach
conditions during fasting. The stir rate was set to 60 RPM and 25 mL of dissolution media was used
per vial for the filament strands and 50 mL for the tablets. At predetermined time intervals, samples
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were withdrawn from vessels, air dried, and weighed. Samples were then placed in the oven for 12 h
at 40 ◦C and weighed again.
2.8. Direct Compression
Dried powder was mixed in a Universal Motor Drive (UMD) 400 (Pharmag GmbH, Klipphausen,
Germany) that was attached to a cube mixer and rotated at 50 RPM for 15 min. The mixed batch
was dried for a period of 12 h in an oven (Sanyo Gallenkamp, Loughborough, UK) at 40 ± 0.1 ◦C
before being dry compressed for the manufacturing of compressed tablets. The tablet press used was a
manual Atlas Series laboratory hydraulic press (Specac Limited, Orpington, UK) capable of 15 tons
of pressure. The die was a hardened stainless steel evacu-able pellet die Specac GS03000 (Specac
Limited) that produces tablets or disks with a diameter of 13 mm. Tablet formulations are in Table 2.
About 500 mg of powder was accurately weighed on a Sartorius analytical balance (Sartorius, Weender
Landstr, 94-10837075 Göttingen, Germany) and fed into the die. The dice and plunger were put on top
of the powder and a 5-ton pressure was applied to the mixture for 30 s.
2.9. Drug Release Studies
Dissolution testing of direct compressed and 3D printed tablets was performed using a Distek
dissolution system 2100B with a Distek temperature control system TCS 0200B (Distek Inc., North
Brunswick, NJ, USA) using to USP Dissolution Apparatus I. The tablets were tested (n = 6) in dissolution
media 0.2 M hydrochloric acid, pH 1.2, and the temperature maintained at 37 ± 0.5 ◦C to mimic the
stomach conditions during fasting. The stir rate was set to 50 RPM with 900 mL of dissolution
mediaused per vessel. At predetermined time intervals, 5 mL was withdrawn from each vessel and
replaced with pre-heated media. The withdrawn samples were filtered through 0.45 µm filter and
drug release determined at 272 nm by performing UV spectroscopy on a Shimadzu UV-1280 UV-VIS
spectrophotometer (Shimadzu, Milton Keynes, UK), which was blanked with a solution of the buffer
and dissolved polymers according to the formulation tested in order to secure the detection of caffeine.
The dissolution profile was observed from a plot of time versus absorbance.
2.10. Scanning Electron Microscopy
Scanning electron microscopy (SEM) was performed on a Mira SEM (Tescan, Oxford Instruments,
Cambridge, UK) using a range of magnifications to evaluate the surface morphology of samples
through the secondary electrons function. Samples were placed in a petri dish and liquid nitrogen
was poured into the dish with enough to completely submerge the samples in the liquid. The lid was
placed on the petri dish and left until the nitrogen totally evaporated, which was immediately followed
by the transversal break of samples. Afterward, the surface of the specimens and the cross-section were
examined. First, the samples were placed on an aluminum stub and were gold coated using Baltec
SCD 005 sputter coater (BAL-TEC GmbH D–58579, Schalksmühle, Germany) for 110 s at 0.1 mBar
vacuum before observation.
2.11. Statistical Analysis
Data handling and analysis was performed using the Minitab 17 (Minitab Ltd., Coventry, UK).
Test data was inputted into the software and, for replicate sets of data, mean and standard deviation
values were calculated. The significance threshold was set at 0.05. The mean values were presented in
the figures included in the results section and error bars represent standard deviation unless otherwise
specified in the figure caption.
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3. Results
3.1. Mechanical Characterization
3.1.1. Filament Stiffness
Filament stiffness over no minimal FFF working range of a select number of melt-blended
formulations are shown in Figure 2. The nominal working range reflects the temperature range the
filament experiences as feed above the driving gear (room temperature) and as a piston below the
driving gear (above 30 ◦C). Addition of 10% (w/w) of the recommended plasticizer P188 (F1) decreased
PVP-VA stiffness at room temperature by 69%. Melt-blending with either PEO or PCL significantly
decreased room temperature filament stiffness (p < 0.05). A 10% (w/w) addition of PEO (F3) decreased
PVP-VA stiffness by just over 66%. PVP-VA stiffness decreased by 48% in addition of 10% (w/w) PCL
(F2) and continued to decrease (75%) with double the amount of PCL (F4). Binary blends of higher
amounts of PCL had no further effect on the PVP-VA room temperature filament stiffness. PVP-VA
was over 200 times stiffer than PCL (306 N/m). Stiffness readings could not be made for PCL at
temperatures above 56.05 ◦C since the polymer had started to melt. At higher piston temperatures,
PVP-VA maintained a constant stiffness up until an inflection point (onset temperature) of 68.66 ◦C.
Above this temperature, stiffness steadily decreased with increasing temperature. While higher PCL
content did not significantly affect room temperature stiffness (p < 0.05), the higher the PCL content,
the steeper the decline in stiffness was with rising temperature. For the final formulation (F11) addition
of 10% (w/w), PEO significantly decreased the stiffness across the entire working temperature range.
Above 60.0 ◦C, there was an abrupt drop-off in filament stiffness for the final F11 formulation.
Figure 2. Stiffness (N/m) of extruded filaments within no manual working range for the FFF
(fused-filament fabrication) process (10 ◦C to 90 ◦C) (n = 2).
3.1.2. Filament Brittleness
Table 4 shows the strain-at-break (εb), storage modulus (E′), and brittleness B × 104 values
obtained from filaments of the different material formulations. The B values (%Pa) were derived
from two separate mechanical tests, quasi-static 3-point bending that calculated εb values (%) and a
room temperature dynamic mechanical test in a single cantilever (1 Hz) calculated the E′ values (Pa).
PVP-VA showed the highest brittleness of polymers and blends with a value of 6.22 %Pa (104) while
PCL had a value that was 94.3% lower than that of PVP-VA at 0.35 %Pa (104). The addition of 10%
(w/w) P188 (F1) to PVP-VA decreased its strain-at-break along with an increase in brittleness by 34%.
In contrast, 10% (w/w) PEO (F3) reduced the brittleness of PVP-VA by 66%. Doubling the amount of
PEO (F5) further decreased the brittleness by an additional 4%. PCL decreased the overall brittleness
of PVP-VA even though the effect was not as strong as that of PEO at the same concentrations. At 30%
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PCL (F6), brittleness values saw a reduction of 81%. F7 is composed of 40% (w/w) PCL and the lowest
value of brittleness was observed at 0.10 %Pa (104). Ternary blends (F9, F10, and F11) containing P188
or PEO in addition to PCL displayed similar low brittleness values of ~0.15 %Pa (104).
Table 4. Brittleness (B) (%Pa) of extruded filaments at room temperature. B values are shown as
multiples of 104 for the convenience of the reader. Storage modulus (E′) was obtained at room
temperature at a 1 Hz frequency (n = 3). Strain-at-break (εb) was obtained using a room temperature
three-point bend testing (n = 5).
Formulation B (%Pa) (104) εb (%) E′ (Pa)
PVP-VA 6.22 0.85 ± 0.19 1897.89 ± 2.27
PCL 0.35 59.07 ± 1.38 481.99 ± 0.04
F1 8.33 0.68 ± 0.08 1768.03 ± 61.47
F2 5.75 0.93 ± 0.12 1877.50 ± 19.19
F3 2.10 2.34 ± 0.85 2033.35 ± 24.26
F4 3.24 2.41 ± 0.67 1277.84 ± 2.76
F5 1.89 2.29 ± 0.82 2314.50 ± 6.26
F6 1.21 3.73 ± 2.28 2223.50 ± 59.54
F7 0.10 78.58 ± 5.65 1295.80 ± 305.20
F8 0.62 13.82 ± 5.34 1175.02 ± 34.18
F9 0.15 54.46 ± 30.79 1223.47 ± 1.55
F10 0.15 73.06 ± 4.15 935.16 ± 1.08
F11 0.14 72.23 ± 6.67 995.94 ± 1.87
3.1.3. Dynamic Mechanical Analysis
Figure 3 displays DMA thermograms for a selected number of formulations including showing the
storage modulus (E′), loss modulus (E”), and tan δ across a broad temperature (◦C) sweep. The storage
modulus (E′) value for PVP-VA steadily decreased until the onset of a relaxation at 65.21 ◦C when
E′ value declined more steeply (see Figure 3a). PCL had a storage modulus peak at −67.86 ◦C of
2479 MPa, which reflects the glass transition temperature (Tg) and with increasing temperature E′
values steeply declined until around −45.00 ◦C when the rate of decline slowed before another sharp
drop prior to melting (see Figure 3b). An addition of 10% (w/w) PCL to PVP-VA (see Figure 3c)
produced a slight peak at −56.22 ◦C of 2463 MPa. This lower temperature peak increased in intensity
and decreased in temperature with increasing PCL content. The inflection point in the storage
modulus (onset temperature) decreased in temperature with increasing PCL content up until 20%
(w/w) (see Figure 3c,d) 62.31 ◦C (F2), and 49.07 ◦C (F4). At 40% (w/w) PCL, the onset temperature rose
to 62.50 ◦C (F7) and at 50% (w/w) PCL, the onset temperature rose further to 76.70 ◦C (F9). For the
final formulation F11, which contained 10% (w/w) PEO, displayed a much steeper storage modulus
decline after Tg (63.81 ◦C) and it should be noted that E′ value at Tg was significantly higher than for
all the binary blends.
The loss modulus (E”) for PVP-VA displayed a sharp peak at 96.37 ◦C (see Figure 3a) while a
sharp peak for PCL was at −59.06 ◦C (see Figure 3b). A secondary broad peak was apparent on
the PVP-VA thermogram at 28.36 ◦C, which may be due to the VA comonomer. Addition of 10%
(w/w) and 20% (w/w) PCL to PVP-VA reduced the temperature of the sharp peak to 75.98 ◦C and
61.31 ◦C and of the broad peak to 23.32 ◦C and 21.45 ◦C, respectively. For F4 (see Figure 3d), a second
lower temperature broad peak appeared at −47.41 ◦C. For F7, with the addition of 40% (w/w) PCL
(see Figure 3e), there was a significant decrease in the intensity of the sharp peak to 36.44 MPa and an
increase in the temperature to 69.19 ◦C. A stronger lower temperature peak appeared at −61.91 ◦C and
was sharper than previous low temperature broad peaks. At 50% PCL content (see Figure 3f), the sharp
peak increased in temperature to 88.50 ◦C and two lower temperature peaks appeared at 36.96 ◦C and
−69.54 ◦C. For the final formulation F11 (see Figure 3g), the higher temperature sharp peak was of low
intensity and appeared at 64.11 ◦C. A distinct but rounded peak was present at −54.59 ◦C.
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Tan δ peaked at 126.68 ◦C for PVP-VA (see Figure 3a), but it is not clearly observed for PCL due
to a noisy signal starting at 55.35 ◦C caused by the onset of melting. For F2, the peak at 121.69 ◦C
corresponds to that of PVP-VA (see Figure 3c). There is no peak for F4 at the higher temperatures
but a shouldered peak is observed around 74.16 ◦C (see Figure 3d). F7 displayed a more pronounced
shouldered peak at 81.09 ◦C after which a crest formed at 131.97 ◦C (see Figure 3e). At 50% (w/w) PCL
content, the shouldered peak was not observed but a strong, sharp peak was observed at 125.54 ◦C
(see Figure 3f). The shouldered peak was present at 67.48 ◦C in the F11 sample, but the machine could
not properly measure data points at higher temperatures (see Figure 3g).
Figure 3. DMA (dynamic mechanical analysis) thermograms for a select number of formulations
displaying storage modulus (E′), loss modulus (E”), and tan δ across a broad temperature (◦C) sweep:
(a) PVP-VA; (b) PCL; (c) F2; (d) F4; (e) F7; (f) F9, and (g) F11.
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3.2. Thermal Characterization
Table 5 displays the thermal properties of all the base polymers and the melt-blended formulations.
Extruder torque is a measure of drive motor resistance due to melt-viscosity of the polymer inside the
barrel [38] and it has been proposed as a measuring tool of the relative viscosities of polymer melts
during the extrusion process [39]. During these studies, the temperatures and screw speed were kept
constant for all formulations. Torque readings are shown in Table 5 for the different formulations.
The highest torque reading was observed for PVP-VA while PCL was the lowest. Melt-blending
PVP-VA with the other polymers reduced torque. Therefore, the resistance due to viscosity was
reduced. The reduction of torque recorded during the extrusion process for mixtures of polymers
when compared to PVP-VA allowed for higher manufacturing throughput. However, processing
conditions were kept constant to guarantee all polymers were submitted to similar stresses during
manufacturing. Both PEO and P188 have a plasticizing effect on PVP-VA, but this phenomenon was
better observed with formulations containing PCL. Surging, which is due to inconsistencies in the
amount of material pushed out the die, was conducted typically in a sinusoidal fashion and was
soothed by the incorporation of PCL. The observed surging could be due to a number of factors such as
material adhering to the screw, feed entry variations in the material particle shape, or inadequate filling
of the metering section of the screw. Higher concentrations of PCL further reduced the inconsistencies
of the extrudate geometry. The final formulation (F11) containing 10% (w/w) PEO was observed to
have reduced instances of surging compared to the binary blends.
Table 5. Extruder torque measurements, melt flow rates of polymers, and melt-blend formulations.
Extruder torque measurements were recorded during twin-screw hot-melt extrusion compounding
and are a measure of melt viscosity.
Name Extruder Torque Melt Flow Rate at 140 ◦C Melt Flow Rate at 150 ◦C
(%) (g/10 min) (g/10 min)
PVP-VA 40 0.00 ± 0.00 5.14 ± 0.12
PCL 10 11.10 ± 0.04 17.23 ± 0.77
F1 15 4.51 ± 0.04 9.51 ± 0.17
F2 20 3.01 ± 0.03 4.65 ± 0.70
F3 15 2.33 ± 0.03 3.12 ± 0.30
F4 20 2.89 ± 0.15 12.42 ± 0.41
F5 15 0.55 ± 0.01 1.8 ± 0.01
F6 15 4.74 ± 0.06 5.88 ± 0.15
F7 10 6.88 ± 0.07 8.37 ± 0.04
F8 10 7.06 ± 0.07 7.24 ± 0.05
F9 10 3.56 ± 0.05 6.93 ± 0.07
F10 10 9.30 ± 0.11 22.87 ± 0.69
F11 10 7.52 ± 0.06 10.53 ± 0.02
Melt flow indexing is a simple test that measures the ability of a polymer to flow when in the
molten state at a given temperature. The melt flow rates for polymers and blends are shown in Table 5
for both the temperature during HME (140 ◦C) and the established printing temperature (150 ◦C).
PVA-VA had no melt flow at 140 ◦C along with PEO while P188 and PCL had the higher values
of all polymer and formulations, 26.4 g/10 min, and 11.1 g/10 min, respectively. There is a direct
correlation between the amount of PCL incorporated into PVP-VA and increasing MFR values with
melt flow increasing from batches with 10% (w/w) PCL (F2) up to 50% (w/w) PCL (F8) by 4.1 g/10 min.
PEO increased the melt flow of PVP-VA to a lesser degree than PCL. However, doubling its content
from 10% to 20% (w/w) had the opposite effect by decreasing MFR values from 2.3 g/10 min to
1.8 g/10 min. F10 and F11 were found to possess the greater amount of melt flow with 9.3 g/10 min
and 7.52 g/10 min, respectively. At 150 ◦C, PVP-VA flowed at a rate of 5.14 g/10 min, while PCL had
an MFR of 17.23 g/10 min. Addition of 10% (w/w) of both P188 and PEO to the base polymer increased
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MFR of PVP-VA, with the P188 blend doubling the MFR. Addition of PCL to the PVP-VA increased
the melt-flow rate. Adding 10% and 20% (w/w) PCL had a similar effect on melt-flow while increasing
content up to 50% (w/w), which was shown to double the MFR. Ternary blends had differing effects
on melt-flow depending on the third polymer. Adding 10% (w/w) PEO reduced MFR and adding 10%
(w/w) P188 increased MFR. The final material formulation, which contained 60% (w/w) PCL and 10%
(w/w) PEO, had an MFR of 10.53 g/10 min at 150 ◦C.
Figure 4 shows the DSC thermograms of cooling (a) and heating (b) for PVP-VA, PCL, PEO, and
the final formulation F11. PVP-VA is amorphous and thus did not generate a melting peak. The glass
transition (Tg) temperature of the polymer was 100.1 ◦C, which calculated from relaxations observed in
DSC thermograms (Figure 4b) (n = 4) and is close to the peak observed at 96.32 ◦C in the loss modulus
(see Figure 3a). A melting peak was observed at 57.9 ◦C for PCL while crystallization happened at
21.1 ◦C. PEO melted at 67.5 ◦C and solidified at 31.1 ◦C. The main melting peak for F11 occurred at
57.0 ◦C with a small shoulder at 62.2 ◦C. The main peak would represent the PCL portion of the ternary
blend while the shoulder would represent the 10% (w/w) PEO portion. From the cooling cycles, two
solidification peaks are observed at 30.4 ◦C and 43.2 ◦C, which would again represent PCL and PEO,
respectively. A 5% (w/w) caffeine loading to F11 did not produce a melting peak at 235 ◦C to 237 ◦C
and it did not alter the MFI values of the formulation. Therefore, further characterization is beyond
the scope of this body of work (data not shown).
Figure 4. Overlaid DSC (differential scanning calorimetry) thermograms of the three base polymers
and the F11 melt-blended formulation: (a) cooling and (b) heating.
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3.3. Dissolution Studies
3.3.1. Mass Loss
The mass loss of select blends was measured over a period of 8 h to ascertain the effect of changes
in material formulation on the disintegration profile of PVP-VA. Figure 5 shows the remaining mass (%)
over time of a formulation filament in biologically relevant media. PVP-VA was shown to completely
disintegrate within the first two hours, which would be expected for a polymer designed for immediate
release applications. Adding PCL to the formulation slowed the rate of mass loss. Adding 10% (w/w)
PCL reduced mass loss to 42.4% in the first 2 h by increasing to 82.8% at 4 h and only a tiny 3.1%
portion remained after 8 h. Doubling the amount of PCL to 20% slowed mass loss even further, and
after 4 h, more than twice the amount of mass remained (45.7%) compared to the 10% PCL sample.
After 8 h, more than a fifth of the mass remained (21.7%) for this formulation. At higher PCL loadings,
the linear pattern stopped. The sample containing 40% PCL is of particular note since it lost 44.8%
mass after 4 h but regained 11.8% after 6 h. The formulations with a content of 50% (w/w) PCL and
more displayed a slower rate of dissolution in media with more than 75% of their mass still intact after
an 8 hour-period.
Figure 5. Percentage of mass loss in HCl media, pH 1.2, 0.2 M at different time points. Percentage
values in legend correspond to PCL (polycaprolactone) content (w/w %).
3.3.2. Cumulative Drug Release
The influence of material formulation and tablet manufacturing processes on drug release over 48
h is shown in Figure 6. Two compressed tablets of different formulations (30% and 60% (w/w) PVP-VA
content) both released over 75% drug content after 6 h. Similarly, a 3D printed tablet containing 30%
(w/w) PVP-VA released 78.3% drug after 6 h. There was no significant difference in the release profiles
of these three tablets (p < 0.05). The presence of PCL in the formulation slows caffeine drug release
and the immediate release properties of PVP-VA. A PVP-VA compressed tablet released 100% drug in
under 1 h (data not shown). For a 40% (w/w) PVP-VA 3D printed tablet, the cumulative release was
not significantly different for time points up to 6 h. Beyond this point, the cumulative release from the
tablet slowed significantly compared to other tablets. After 8 h and 24 h, the tablet had released 83.8%
and 97.3% drug, respectively. There was a significant difference in the release profile of the 30% (w/w)
PVP-VA 3D printed tablet and the other tablets at almost all time points. After 6 h, this tablet released
38.5% of the drug with 50.1% release of the 30% (w/w) PVP-VA 3D printed tablet. After 24-h release
increased to 80.1% and, after 48 h, the release was 92.3%.
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Figure 6. Cumulative caffeine release over 48 h in HCl 1.2 pH, 0.2 M media for different tablet
formulations produced via direct compression. Percentage of PVP-VA (polyvinylpyrrolidone-vinyl
acetate) reflects material composition only, which contains 10% w/w PEO (polyethylene oxide)
with the remainder being composed of PCL. All formulations contain 5% w/w caffeine in the
overall composition.
4. Discussion
4.1. Material Formulation Rationale
PVP-VA is a copolymer of polyvinylpyrrolidone (PVP) and vinyl acetate (VA). The addition of
the VA side chains increases the hydrophobicity of PVP. The polymer has previously been used in the
production of amorphous solid dispersions [40–44], as a release modifier [45], and has been blended
with PCL for the production of tissue engineering scaffolds [46,47]. Our initial HME trials to produce
PVP-VA filaments for FFF were unsuccessful. The material proved to be brittle and the filament
would snap during the HME downstream haul-off process. Therefore, our approach was to modify
PVP-VA sufficiently through melt-blending so that it would form a suitable filament. We aimed to
find a material formulation incorporating PVP-VA, which would permit the production of a complete
batch (n = 40) of flat-face plain tablets during a single print run. Kolliphor® P188 is the recommended
plasticizer by the supplier BASF® [34]. In addition to the plasticizer, there were no observable changes
in the flexibility of the filament. Very high loadings of P188 produced extrudate that would crumb and
not form consistent filaments. Therefore, other polymers were investigated to blend with PVP-VA.
Blending during the HME process is a means of combining properties of different polymers
into a single final object [48]. Melt-blending is not a new concept in drug delivery as with industrial
applications. It is a means that provides the final dosage form with refined or a broader set of properties.
We have previously reported on blending polyethylene vinyl acetate (PEVA) with polylactic acid (PLA)
to improve the release of hydrophilic tenofovir from PEVA intravaginal rings [49]. The production
of solid dispersions has benefited greatly from melt-blending. Polyethylene glycol (PEG) is by far
the most widely used polymer in the production of solid dispersions due to low melting points, fast
solidification behavior, and low toxicity [50]. However, such formulations made from the polymer are
unstable. Some authors have described the positive impact of melt blending [40,50,51]. Bley et al. [40]
describe the production of solid dispersions of PEG and different polymers via co-melting. The addition
of polymers was aimed at stabilizing amorphous forms of water-insoluble drugs in PEG-based solid
dispersions. The researchers found that blends of PEG with PVP-VA were less viscous than the
pure polymers and that the PEG/PVP-VA blend created the best solid dispersion regarding both the
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dissolution rate and amorphous drug stability for both drugs. Therefore, melt-blending and careful
polymer selection provided an advantage compared to using a single polymer.
Melt-blending for FFF has been described a number of times in prior studies. Rocha et al. [52]
described the production filaments from acrylonitrile butadiene styrene (ABS) based binary and
ternary polymer blends. The printed parts produced from the blends displayed different mechanical,
physical, and surface properties compared to the neat ABS samples. Printability could be maintained
across a broad range of compositions and miscibilities. Roberson et al. [53] described the utilization of
melt-blending to develop materials for specific applications and how it can be used to overcome specific
shortcomings inherent to printing with the neat polymers. The same group described melt-blending
ABS with thermoplastic elastomer styrene ethylene butylene styrene (SEBS) grafted with maleic
anhydride to produce a flexible material suitable for the production of actuators [54]. Through
melt-blending, the authors were able to produce prints with comparable performance to those using
higher cost polyurethane filaments. Although the majority of other studies are concerned with
non-pharmaceutical polymers [55–57], some researchers are examining melt-blends in FFF for medical
applications. Kosorn et al. [58] produced blends containing different compositions of polycaprolactone
(PCL) and poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBHV) for porous scaffolds. Higher
PHBHV content improved compressive strength, increased chondrocyte proliferative capacity, and
enhanced chondrogenic potential. Alhijjaj et al. [26] used melt-blending to improve printability and
control drug release from printed solid dispersions. The researchers created Eudragit EPO or Soluplus
based blends with PEG, PEO, and Tween 80 and achieved excellent printability and drug dispersion.
Blend composition had a significant influence over disintegration behavior and rates of drug release.
Since PVP-VA proved to be unprintable due to brittleness and high stiffness, our strategy was to
melt-blend PVP-VA with another polymer that had the inherent flexibility and ductility. Ideally, the
polymer would also be well-established for FFF 3DP, drug delivery, and be biocompatible. One polymer
that fits the criteria is PCL. The polymer has a long history in the FFF 3DP and one of the earliest
research articles on FFF for biomedical applications described the use of PCL in the production of a
scaffold [59]. PCL-based drug delivery systems present high drug permeability, excellent compatibility
with many drugs, and full excretion from the body once absorbed, which makes the polymer an
excellent choice [60]. A possible disadvantage of PCL is the slow degradation rate that would likely
impede the immediate release properties of PVP-VA, but this was not a hindrance for us since our main
consideration was to use a material that could be utilized in HME, direct compaction, and injection
molding. For the interested reader, a recent paper by Solanki et al. [61] describes a formulation
strategy for FFF that maintains the immediate release properties of PVP-VA through melt-blending
with hydroxypropyl methylcellulose and hydroxypropyl methylcellulose acetate succinate. PEO was
also included in the current formulation trials since we wished to reduce the hydrophobicity of the
PCL [62]. We have previously had success blending PCL with PEO to form an oral tablet [38] and such
blends have been reported elsewhere as efficient drug carriers [63–65].
4.2. Filament Production
For our purposes, we wished to melt-blend polymers with drug and create filament in a single
step. To do this requires the use of a twin-screw extruder that provides for better mixing of the drug
within a polymer compared to a single screw extruder [30]. Figure 7a,b show our filament extrusion
setup and Figure 7c is the design of the die attachment that was attached to the front-face of the
twin-screw extruder. The conical design for the attachment allows for an increase in die pressure
without applying excessive shear force on the polymer melt since excessive shear can degrade certain
polymers [66]. The design also permits for a steady flow of material out of the extruder. The consistency
is a key feature needed for the manufacture of FFF filament strands since the margin of tolerance for the
dimensions of the extrudates is narrow. The strands needed to have a diameter of 1.75 mm ± 0.10 mm
to pass through the driving gear and into the liquefier. Any values below or above this range are not
feasible as a feedstock material for the MakerBot® 3D printer.
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Figure 7. Depiction of machinery used for the fabrication of formulations described in this body of
work: (a) twin-screw extruder, (b) mounted die attachment on extruder flange, and (c) schematic of
die attachment.
The front orifice of the die attachment was designed with a diameter of 2.30 mm, which allowed
the extruded filament to be larger than needed so that control of the filament diameter was completed
through subsequent unidirectional stretching by the haul-off units. Since we did not have access
to a melt-pump system, compensation for extrusion surging was through operator control of the
haul-off speed. The extrudate filament was cooled through a system of air knives and not through a
water-bath to prevent erosion of the water-soluble polymer filament and drug loss. The haul-off system
was in two stages: a first Teflon belt at a 45◦ decline with air knife cooling and a second twin belt
conveyor that was the dominant haul-off controller. Figure 8 shows the physical appearance of a select
number of filaments produced during HME trials. The majority of formulations gave filaments with a
rough surface, which is indicative of the onset of sharkskin. The sharkskin appearance is indicative of
instabilities in the flow exiting the die [67] and is probably related to the immiscible portions of the
melting portion. Higher die temperatures may have resolved the issue. Both polymers, PVP-VA and
PCL, and F6 all produced filaments with a smooth surface with no sign of sharkskin, which suggested
stable melts at these processing temperatures [67]. For the most part, the die attachment reduced
surging from the twin-screw extruder, but some operator intervention was still required to maintain
tolerances. Addition of 10% (w/w) PEO had the unexpected benefit of almost eliminating extrusion
surging in the final 60% (w/w) PCL formulation.
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Figure 8. Physical appearance of filaments from select formulations made via hot-melt extrusion.
4.3. Filament Characterization
For PVP-VA printability to improve, it had to be modified to remove brittleness and decrease stiffness.
Figure 2 shows stiffness of the filaments for a select number of formulations. On melt-blending, with
the other polymers, the stiffness was reduced sufficiently to permit coiling. We estimate from our data
that filament stiffness should not exceed 1000 N/m to enable consistent coiling. In addition, from our
experience, as stiffness surpasses 10,000 N/m, the printable length of filament shortens. Filaments must
also be able to resist buckling after the driving gear due to the force applied during feeding since
the filament acts as a piston on the molten polymer in the liquefier [33,68]. Venkataraman et al. [68]
derived a relationship of elastic modulus (in compression) to apparent viscosity in which a critical
ratio (3.00–5.00 × 105 s−1) ensures a material will not buckle during FFF, i.e., the filament is sufficiently
stiff to act as a piston and drive out molten polymer in the liquefier through the nozzle. Insufficient
stiffness was not an issue for PVP-VA and the reverse was more of a concern since the filament could
not be coiled for proper feeding. The column strength critical ratio to prevent buckling can be assumed
to have been maintained since buckling was not observed. We were unable to directly calculate the
ratio without access to a capillary rheometer.
The second main issue with PVP-VA was the inherent brittleness that created issues during
filament production and feeding of the FFF extrusion head. To quantify brittleness, the Brostow-Hagg
Lobland-Narkis equation for Brittleness (B) (Equation (2)) was used [37]. Strain-at-break (εb) is a
measure of a material’s ductility and is usually recorded during tensile testing as elongation-at-break
(%). Storage modulus (E′) is the solid-like (elastic) response to stress and is usually recorded during
dynamic mechanical analysis (DMA). The authors specify the DMA conditions at room temperature
for a frequency of 1 Hz. The elegance of this equation is that it requires results from two forms of
mechanical testing—quasi-static and dynamic. For convenience, we took results directly from extruded
filaments and not tensile specimens. Therefore, we derived brittleness (B) from strain-at-break (εb)
values obtained from 3-point bend testing by using deflection rather than elongation values. The true
value of this approach derives from direct testing of filaments with comparable stress (flexural) applied
to filament passing through the driving gear system. The equation should enable researchers to
prescreen material formulations for suitability. Since the driving gear mechanisms of different FFF
printers will vary, researchers can determine the critical brittleness (Bc) for their system, above which
it will be known that the filament will fail. The results in Table 4 aided us in quantifying observations
about filaments that had failed to print since the filaments that had failed to negotiate the Makerbot®
system had B values higher than 2.00 %Pa (104). Thus, B < 0.0002 %Pa will be a critical material
characteristic for future material formulations for this printer.
Figure 9 shows the finished print of a complete batch of tablets. Part of the pre-screening process
is to calculate the length of filament required to print a complete batch of 13 mm diameter tablets.
Most printer software will pause a print mid-run to permit changing of the filament and, therefore, it
is not an insurmountable issue, but from a purely practical point-of-view, it is important to be aware of
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how large of a batch can be printed from a single filament length. Equation (3) was used to calculate
the density (Db) of the ternary blend F11 (0.001141 g/mm3). The total volume (VT) of forty 4 mm
high (cylinder) tablets was 21,237.16 mm3 (Equation (4)) where hTs is the total height of sample tablets
combined and rs is the radius of the tablet. The total mass (MT) to print forty 100% infill tablets was
calculated at 24.23 g (Equation (5)). Finally, the length of required 1.75 mm diameter filament to print
forty 100% infill tablets could be calculated as 8829.32 mm using Equation (6) where rf is the radius
of the filament. We refer to this as the minimum batch length (LB). The filament length should be
adjusted for the percentage infill (x) of samples, e.g., 0.25 for a 25% infill, which reduces the length to
2207.33 mm. In addition, to account for variation in filament diameter and the material needed for
the outer shell, a correction factor of at least 1.3 should be applied, which would bring the minimum
batch length (LB) for these tablets to 2869.53 mm. In further criteria, we set any material formulation
is the minimum sample length (LS), which is the minimum filament length to print a single sample
without operator intervention. The LS for this design of flat-face tablet with 25% infill is 71.74 mm.
We consider LS to be the minium criteria of viability for any material formulation for the FFF process.
PVP-VA could not pass this minimum criteria (LS) due to brittleness. F5 was the first formulation to
pass this criteria, but only F11 could succeed in passing the minium batch length (LB) and provide a
filament in excess of 8.83 m. To achieve the LB required for the quite high PCL content, it ultimately
reduced the drug release rate (see Figure 6). Therefore, printability versus the drug release profile is a
choice that can guide future formulation. We can maintain more of the immediate release properties
of PVP-VA by reducing PCL content but at the cost of the filament length and subsequent batch size.
Ls is the limit at which PCL content can be reduced.
Figure 9. Complete batch of flat-faced tablets produced via FFF 3D printing. Total of 40 tablets covered
the print bed of MakerBot Replicator 2X.
Db = x1D1 + x2D2 + x3D3 (3)
VT = pihTs r
2
s (4)
MT = DbVT (5)
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2
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4.4. 3D Printing of Flat-Faced Tablets
Formulation F11 was chosen for the material blend’s ability to overcome the physical restrictions
of the FFF process and to form a consistent filament to be fed to an extrusion head. Filament is usually
spooled at the point of production on the downstream equipment. Spooling is usually the most
convenient approach with spools sold in ~1 kg batches. However, it is possible to create successful
prints with unspooled filaments if it is unobstructed and can move freely. Figure 9 shows the finished
print of a complete batch of tablets. Forty 13 mm diameter tablets is the maximum number that could
be consistently printed on the print bed of the Makerbot® system. The print-bed is covered with a
Pharmaceutics 2018, 10, 44 18 of 27
disposable high-temperature Kapton® polyimide tape, which glues the first layer deposited. No raft or
support structures are required for flat-face tablets. The outer wall of tablets was made by one solid
shell. The roof and floor were also solid and had a depth of 0.5 mm. Infill density was set to 25% and
the infill pattern was linear. These settings create a tablet with a shell structure with 75% of its inner
volume consisting of void space.
Figure 10 shows examples of the main types of part failure during the FFF process. Stringing
(see Figure 10a) occurs when excess material on the nozzle is dragged from the part during
manufacturing. The problem is more pronounced for materials with a high melt strength that will
readily allow for stretching of molten beads. Some printing software has a ‘retraction’ countermeasure
setting that eases back pressure in the extrusion head to prevent oozing from the nozzle during print
head travel. Other reasons that could cause this flaw are two high nozzle temperatures that cause low
material viscosity over extrusion of material and slow cooling of deposited material due to high print
bed temperatures. Layer splitting (see Figure 10b) occurs due to inadequate layer coalescence during
deposition. The polymer chains in the depositing molten layer must intermingle with the polymer
chain of the previous layer to achieve proper coalescence. If adequate coalescence is not achieved,
then during cooling, elimination will occur and layers will split apart. Higher printing and print-bed
temperatures will overcome this issue since lower viscosities and softening of printed layers will both
promote coalescence. Warping (see Figure 10c) is a phenomenon that is not restricted to FFF but occurs
in other processes including injection molding [69]. In the FFF process, it occurs due to poor adhesion
of the base layer to the print-bed and when subsequent layers are deposited on top. Internal stress
between the layers of the print causes the part to warp and curl away from the print-bed surface.
One of the main reasons for warping is the too low print-bed temperature that creates an excessive
thermal gradient [70].
Figure 10. Most common print deformities that occur during the FFF 3D printing.
Infill determines the amount of material printed between the outer shells of a 3DP part. A weak
infill (see Figure 10d) will fail to provide inner support to the part, which compromises the final
mechanical integrity. Weak infill can be caused by choosing the wrong infill pattern for the specific
inner geometry of the part. Too high a printing speed that prevents consistent layer deposition
and poor layer deposition as a result of inconsistent feeding due to problems with the feedstock
or melt-feed. Misalignment (Figure 10e) is due to discrepancies in the printers and the x-y-z axis
dimensions. Most FFF printers have an open loop system without feedback sensors, which means that
the printer will print the preprogrammed CAD design regardless of any misprint in the previously
deposited layers. Assuming the print-bed is properly calibrated, the operator must manually adjust
program settings based on the performance of the material to ensure that the settings (print speed,
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layer height, layer thickness, and more) are achievable. Other reasons for misalignment are related
to hardware issues such as deficiencies in the stepper motor or tension belts. Relatedly, dimensional
accuracy (see Figure 10f) is caused by extrusion problems, print-bed calibration accuracy, and filament
quality. Any fluctuation in the material being deposited will disrupt the dimensions of the part while a
nozzle that is closer or further than intended from the printing bed will have a similar consequence to
the former.
4.5. Tablet Properties
Mass loss and drug release studies were used to assess the effect of changing material formulation
for dissolution. As would be expected, adding a hydrophobic PCL to the PVP-VA had a significant
retardation effect on the mass loss rate (see Figure 5). The PCL content significantly reduced the drug
release rate (see Figure 6) while PVP-VA fully released drugs within the first hour. The 60% (w/w)
PCL took over 8 h to complete. For us, the immediate drug release properties of PVP-VA was not a
critical factor for our tablets and was chosen for the suitability for both direct compression and HME
tablet production processes. If immediate drug release had been a critical factor, then our material
formulation could easily have been changed to suit this criterion. For example, the PEO content
could have increased or we could have chosen a water-soluble polymer such as polyvinyl alcohol
instead of PCL. Melt-blending has the inherent flexibility to change formulation at will to meet such
needs. The different nature of the manufacturing processes influenced the release rate of the drug
substance of tablets with the same formulations (see Figure 6). The HME process intimately mixes
polymer chains in the molten state and they remain entangled when solidified. DC tablets contain the
polymers as powdered mixtures that form strong interparticulate bonds during compression, but the
polymer chains are not entangled. In addition, the DC tablet containing 60% (w/w) PCL completely
disintegrated after 8 h, which enabled the total release of the drug.
The DMA thermograms show that the binary blends of PVP-VA and PCL are only partially
miscible. Complete miscibility of binary blends usually coincides with the formation of a single Tg
peak [71]. Tan δ peaks for the binary blends show that increasing PCL content produced two distinct
Tg peaks, but these peaks moved closer together as PCL content increased. This is characteristic
of partial miscibility [72]. The absence of two distinct Tan δ peaks with increasing PCL up to 20%
(w/w) PCL and the appearance of two distinct peaks at higher loadings would suggest that PCL is
miscible in PVP-VA up to 20% (w/w) content. Mass loss and drug dissolution data both suggest that
when the PCL exceeds 20% (w/w) of the composition, the PVP-VA becomes entrapped with the PCL
matrix as domains. Figure 11 shows SEM scans of the polymers and formulation F11 (containing 5%
(w/w) caffeine). The increase in mass after 4 h during the mass loss study for the F6 and F7 blends
could be due to the swelling of the PVP-VA domains encapsulated by the PCL matrix from ingress of
media. SEM of the printed F11 tablet was inconclusive with regard to miscibility, other than showing
that the morphology of the ternary blend was highly disordered. The open structure of 25% infill
tablets is very clear. Monoclinic caffeine is clearly distinguishable and a white spongy layer is also
visible. Since PVP-VA is glassy, it is more likely that this spongy layer is a PEO domain. The presence
of PVP-VA is not readily discernible. Since miscibility was unimportant to us, it was not studied
beyond the scope of the data presented and would warrant much deeper investigation to pick apart
the miscibilities present within the ternary blend. Miscibility is only a criterion for FFF of solid dosage
forms if immiscibility is detrimental to the performance of the filament or significantly impairs the
performance of the final dosage form. In this study, as with others [52], any blend immiscibility did
not impede the printing of parts.
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Figure 11. SEM scans of the three polymers and the final ternary blend containing 5% (w/w) caffeine:
(a) PVP-VA filament cross-section; (b) PCL filament cross-section; (c) PEO filament cross-section; and
(d) 25% infill 3DP tablet cross-section of F11.
4.6. Material Considerations
Figure 12 is a detailed schematic of an FFF extrusion head. It is best to consider the material in
relation to each of the three zones of the FFF process—feed, heat, and deposition—since each zone
has a specific set of challenges. The feed zone is governed by the bulk properties of the filament,
which entails how successfully it copes with the driving gear mechanism. For the MakerBot® printer,
the driving gear system is part of the extrusion head assembly and, therefore, feeds directly into
the liquefier. These are known as direct drive extruders. On other FFF printers, the driving gear
mechanism on the side of the printer at a distance removed from the extrusion head is known as a
Bowden extruder. The filament is driven along feed tubing to the extrusion head. Such a system
severely restricts the material that can be printed since the filament has to be sufficiently flexible and
aqueous to navigate the feeding tube. Our recommendation to other researchers who are producing
filaments via heat-melting extrusion is only to purchase FFF printers that have the direct driving gear
feeding system since it provides much-valued leeway for printing compared to a Bowden system.
The heating zone is dominated by the material’s response to being heated in a chamber. A suitable
material should be able to form a consistent melting factor in the most efficient manner. Innovation in
this section is related to the heating elements by providing uniform, stable heat flux and eliminating
hot-spots and dead zones so that the length of the liquefier is consistently heated. For the deposition
zone, the material properties are dominated by the behavior of the material to flowing, cooling, and
the ability to adhere to the previous layer or print-bed. Nozzle improvement aims through innovative
design to eliminate or reduce known problems in layer deposition such as die swell and to improve
print resolution. It is important to note that advances in driving gear and extruder head technology
is more than an annual occurrence and existing printers can be retrofitted in most instances with
extrusion heads that will accommodate a wider range of materials than what was previously the
case. Advances aim to reduce extrusion head weight, increase reliability and repeatability, improve
print resolution, and expand the range of materials that can be printed consistently such as softer
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thermoplastics. Table 6 is a compilation of the critical material properties that must be considered
when approaching the production of solid dosage forms via fused-filament fabrication.
Figure 12. Detailed view of an FFF printer extrusion head with parts identified. The three distinct
zones of the process are labelled and nine of the main material considerations are listed beside the
sections of the extruder head in which they exert the most influence.
Table 6. Critical material properties for each zone of the FFF process and comments on each property
based on experimental observation and from prior studies.
Zone Material Property Comments
Feed
Filament stiffness
A very stiff filament will not permit winding onto spools. Therefore, the filament remains in
the vertical axis and length will be limited by room height or other obstructions. Above a
certain stiffness, feed length will be determined by height, which can self-support weight.
For pre-screening, material stiffness can be measured in a number of different modes, tensile,
flexural, or torsion. We utilized a DMA in the single cantilever, but a universal tester (tensile,
flexural, and torsion) or a texture analyser can also be used [13,73]. Zhang et al. [13] allocated
the breaking stress as a quantification of filament stiffness as tested by using a
texture analyzer.
Filament brittleness
Brittle filaments can snap in the driving gears and prevent feeding.
Brittleness (B) can be calculated from strain-at-break (εb) and storage modulus (E′) using the
Brostow-Hagg Lobland-Narkis Equation (see Equation (2)) for brittleness [37]. Primarily
elongation-at break (%) is the value calculated for εb and the values are obtained from tensile
testing if the correct test specimens are available [74]. Our modified approach was to test
filament lengths to obtain strain-at-break from 3-point bending directly. Others have
performed similar tests but solely defined the strain-at-break data as a brittleness
measurement [13,73]. We calculate that B should be less than 0.0002 %Pa for materials to
make suitable filaments.
Column strength
Since most filaments act as a piston on the melt-front in the liquefier, the ability of the
filament to withstand compressive force without buckling is an important variable [68,75].
Venkataraman et al. [68] determined a critical ratio for ceramic-based filaments above which
a filament will withstand buckling. The ratio states that, if the elastic modulus of the filament
is greater than the apparent viscosity by 3–5 × 105 s−1 then the filament will maintain
sufficient column strength during printing.
Most thermoplastic materials will maintain the critical ratio [75], but it is a useful
pre-screening tool for untypical materials or highly-filled materials.
Filament softness
Soft materials can be squeezed between driving gears, which would limite or prevent feeding.
Material hardness can be measured a number of ways, but the Shore durometer method is
the most common approach [76].
Dimensional consistency
Filament consistency will determine the feed rate to the heating end.
Consistency is more than just a measure of filament diameter and can include ovality,
pockmarks, gaps, and general deformities.
Visual inspection is sufficient for eliminating the majority of the irregular filament.
Filament diameter
Diameter ultimately determines feed rate to the heating end. Inconsistent filament diameter
will result in inconsistent deposition and poor prints.
Extrusion flow surging is a problem that occurs due to fluctuations in the feed or transition
zone in the extrusion process [45]. A melt pump will eradicate the problem and produce a
uniform filament but at added capital cost.
Consistent material feeding and a correct temperature profile that permits stable melt
formation can eliminate most surging. Die design can reduce the phenomenon and a longer
land length by promoting a consistent melt output.
Filament diameter is best measured at the point of filament production using laser
micrometers or ultrasonic gauges.
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Zone Material Property Comments
Hot
Melt viscosity
As material softens and begins to melt, feeding from the melt to the nozzle is dependent on
the back pressure formed due to the action of the driving gears forcing the
filament downwards.
High viscosity and the back pressure will be insufficient to force the melt through the nozzle
die. Too high a force can lead to buckling of the filament [68].
Low viscosity and too much material will be pushed through the nozzle by preventing
proper deposition.
Melt viscosity is determined by a rheometer. A capillary rheometer at low shear is best suited
since it most closely resembles the FFF extruder setup.
Softening
Filament entering past the driving gear acts as a piston on the molten polymer below and,
therefore, must maintain sufficient stiffness before melting to create the required back
pressure. If the filament softens too soon, piston action efficiency will decrease and hinder
melt deposition.
A DMA storage modulus curve is a good representation of the stiffness of the material over
an elevated temperature range.
Deposition
Melt flow rate
Melt flow rate is related to viscosity and is temperature dependent.
High flow rate materials will more easily be pushed through the liquefier and nozzle.
Too high and melt deposition will be uncontrollable.
Low flow rate materials will be harder to push through the liquefier and nozzle. Too low of a
flow rate and melt deposition becomes unachievable.
The melt flow rate is determined by a melt flow indexer.
Wang et al. [77] have recently determined that commercial filament grades should be greater
than 10 g/10 min to achieve acceptable print quality.
Melt feed consistency
The homogeneous flow of material is a critical necessity for a successful 3DP part.
Surge feeding or starvation of material result in imperfection in the part’s building process.
Most common signs of feed inconsistency are missing layers, layers misalignment, weak
infill, low dimensional accuracy, and layer splitting.
Feedstock material with consistent dimensions is crucial.
Coalescence
Poor layer coalescence leads to inconsistencies in the structure of the printed parts, which
creates critical points of failure, poor performance, and geometrical discrepancies.
Coalescence increases with decreases in melt viscosity since there is greater polymer chain
mobility and intermingling between layers [78]. Therefore, poor interlayer adhesion may be
improved through higher printing temperatures.
If deposited layers fail to adhere, print quality suffers considerably. Finished parts with the
strong layer-to-layer union will possess higher mechanical toughness [79].
Shrinkage and Warpage
Parts with subpar adhesion to the printing bed could exhibit warping due to deposited layers
cooling down and contracting because of internal stresses, which results in
partial deformation.
If material fails to stick properly to the printing bed, a higher printing bed temperature might
be necessary.
The use of Kapton tape or Scotch™ blue painters tape improves the adhesion of materials to
the printing bed and protects the bed from scratches.
Environmental conditions, such as room temperature, should be taken into consideration
when dealing with poor adhesion or warping since thermal gradients are the primary cause
of internal stress [70].
Correction factors can be applied at the design stage to accommodate for known print
shrinkage of specific materials. These factors are prevalent for common materials and are a
common feature of 3D printing software. Kaveh 2015 et al. [80] describe a means for
determining correction factors for material through the printing of a series of cubes,
cylinders, and stairs.
Moisture content
Trapped water will evaporate by exiting the nozzle and creating bubbles inside the extruded
material, which disrupts the steady deposition of layers [81].
When using hygroscopic materials for long printing processes, it is important to consider the
storage conditions of the feedstock material used for manufacturing. Production could fail
due to absorption of moisture by the material. Adequate drying procedures should be
adopted for an improperly stored filament.
Die swell
Die swell is a well-established issue in polymer extrusion. The phenomena relates to the
exiting diameter of the extrudate being greater than the diameter of the die and is related to
the viscoelastic nature of the polymer. Die swell increases with increasing polymer molecular
weight. It will affect the quality of the final print since it reduces the dimensional accuracy of
the deposited layer.
Die swell from the liquefier nozzle may be reduced through changes to the material
formulation or changes in the nozzle design. However, the short land length of FFF printer
nozzles may preclude the latter option. The primary means of dealing with die swell is to
accommodate the design by specifying the deposited layer thickness to be 1.2–1.5 times the
nozzle die diameter [82].
Material die swell can be measured using a capillary die rheometer [83].
5. Conclusions
Fused filament fabrication is an HME-based 3D printing process that is finding increasing utility
in pharmaceutical applications. However, the ready-use of established matrix polymers is limited
due to the physical restrictions imposed by the mechanics of the process. We have described in detail
the main considerations to be undertaken at each of the three zones of the standard fused-filament
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fabrication printers. We have also described an HME melt-blending approach that can be readily
adopted by others for the production of solid dosage forms. Melt-blending is a well-established,
cost-effective, and convenient means of combining the properties of two or more polymers into a single
matrix material. The final properties of the matrix material can be altered by changing the composition
of the polymers. For the formulation scientist, the melt-blending framework is suitably flexible to
accommodate both the requirements of the final dosage form and any physical shortcomings of the
main matrix polymer under evaluation during fused-filament fabrication.
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